| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6916941 | ALLERGAN | Crystalline composition containing escitalopram |
Aug, 2022
(1 year, 1 month ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7420069 | ALLERGAN | Crystalline composition containing escitalopram |
Aug, 2022
(1 year, 1 month ago) | |
|
US6916941 (Pediatric) | ALLERGAN | Crystalline composition containing escitalopram |
Feb, 2023
(7 months ago) | |
|
US7420069 (Pediatric) | ALLERGAN | Crystalline composition containing escitalopram |
Feb, 2023
(7 months ago) | |
Lexapro is owned by Allergan.
Lexapro contains Escitalopram Oxalate.
Lexapro has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Lexapro are:
- US7420069
- US6916941*PED
- US7420069*PED
- US6916941
Lexapro was authorised for market use on 14 August, 2002.
Lexapro is available in tablet;oral dosage forms.
The generics of Lexapro are possible to be released after 12 May, 2026.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | May 12, 2026 |
Drugs and Companies using ESCITALOPRAM OXALATE ingredient
Market Authorisation Date: 14 August, 2002
Treatment: NA
Dosage: TABLET;ORAL
LEXAPRO family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic